Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Glioblastoma (GBM) is the most common and aggressive form of brain cancers and is the second most common cancer in children only behind leukemia. Conventional therapy consists primarily of surgery, radiation, and chemotherapy, and while these approaches have slightly improved the length of patient survival, there remains no cure for this disease. With the emerging understanding of biology in the process of cancer development, identification of therapeutic targets are being elucidated that will allow more targeted and effective treatment of the disease. This approach is especially important in pediatric brain cancer where conventional therapies may result in damage to the brain causing long-term neurocognitive deficits. We have identified one such target, a protein called the Y-box binding protein (YB-1) that is expressed in adult and pediatric GBM. In those cancer cells it promotes tumor cell growth and also drug resistance making it an attractive target for drug therapy. This project delves into a deeper understanding of how YB-1 controls drug resistance through its partnership with another protein, BMI-1, with the aim of increasing therapeutic efficacy.
Dr. Sandra Dunn
Daniel Radiloff
Hannah's Heroes Foundation
Medicine
Life sciences
University of British Columbia
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.